ReviewCurrent allergy and asthma reports2021
Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for Allergists.
Review in Current allergy and asthma reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Overview of allergic disease: Anaphylaxis - WAO White Book on Allergy 2026 - 2.11.The World Allergy Organization journal · 2026Review
- Pediatric idiopathic anaphylaxis: practical management from infants to adolescents.Italian journal of pediatrics · 2024Review
- Alpha-Gal Syndrome: An Underrated Serious Disease and a Potential Future Challenge.Global challenges (Hoboken, NJ) · 2024Review
- Mast cell activation syndrome: An up-to-date review of literature.World journal of clinical pediatrics · 2024Review
- Predictors of Clonality and Underlying Mastocytosis in Mast Cell Activation Syndromes.Current allergy and asthma reports · 2024Review
- Using the Right Criteria for MCAS.Current allergy and asthma reports · 2024Review
- Rare causes of pediatric anaphylaxis due to obscure allergens.Frontiers in allergy · 2024Review
- When allergies have no name: is idiopathic anaphylaxis driven by co-factors?Frontiers in allergy · 2024Review
- A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Immunoreactive proteins of Capsicum-based spices as a threat to human health: mass spectrometry analysis and in silico mapping.Scientific reports · 2023Article
- Pediatric Anaphylaxis: A 20-Year Retrospective Analysis.Journal of clinical medicine · 2022Article
- Acute Urticaria and Anaphylaxis: Differences and Similarities in Clinical Management.Frontiers in allergy · 2022Review
- The Meat of the Matter: Understanding and Managing Alpha-Gal Syndrome.ImmunoTargets and therapy · 2022Review
- Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of this systematic review is to present the proposed theories of pathogenesis for idiopathic anaphylaxis (IA), to discuss its classification, its diagnostic approach, and management. RECENT
findingsIA represents a major diagnostic challenge and is diagnosed when excluding the possible identifiable triggers of anaphylaxis. The current research, however, revealed that certain conditions including mastocytosis, mast cell activation syndromes, and hereditary alpha tryptasemia can masquerade and overlap with its symptomatology. Also, newly identified galactose-alpha-1,3-galactose mammalian red meat allergy has recently been recognized as underlying cause of anaphylaxis in some cases that were previously considered as IA. IA comprises a heterogenous group of conditions where, in some cases, inherently dysfunctional mast cells play a role in pathogenesis. The standard trigger avoidance strategies are ineffective, and episodes are unpredictable. Therefore, prompt recognition and treatment as well as prophylaxis are critical. The patients should always carry an epinephrine autoinjector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.